HRMY
What one share of Harmony Biosciences Holdings holds
Pharmaceutical Preparations
We are cultivating a differentiated neuroscience company, rooted in innovation and driven by a commitment to addressing the unmet needs of patients living with neurological diseases. To date, we have focused on rare neurological diseases with a growing portfolio now spanning sleep/wake, rare epilepsy, and neurobehavioral and we are harnessing scientific insights and pioneering approaches to advance meaningful treatments that help patients thrive.
Harmony Biosciences Holdings’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $16.35 |
|---|---|
| Profit | $3.09 |
| Cash and investments | $9.46 |
| Debt | $2.65 |
| Book value | $17.19 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | $0.77 | −$24.07 | $0.02 | −$9.72 | — | −$54.30 |
| 2020 | $6.20 | −$2.48 | $0.00 | −$0.12 | — | — |
| 2021 | $5.16 | $0.58 | $0.01 | $1.66 | — | $3.17 |
| 2022 | $7.17 | $2.97 | $0.00 | $2.36 | — | $6.76 |
| 2023 | $9.64 | $2.13 | $0.01 | $3.63 | — | $8.23 |
| 2024 | $12.35 | $2.51 | $0.02 | $3.78 | — | $11.53 |
| 2025 | $14.83 | $2.71 | $0.01 | $5.94 | — | $15.07 |